Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment

HER2-targeted immunotherapy consists of monoclonal antibodies (e.g. trastuzumab, pertuzumab), bispecific antibodies (e.g. MM-111, ertumaxomab) and activated T cells armed with anti-HER2 bispecific antibody (HER2Bi-aATC). Trastuzumab is a classic drug for the treatment of HER2 positive metastatic bre...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Shengnan, Liu, Qian, Han, Xinwei, Qin, Shuang, Zhao, Weiheng, Li, Anping, Wu, Kongming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5704598/
https://www.ncbi.nlm.nih.gov/pubmed/29209558
http://dx.doi.org/10.1186/s40164-017-0091-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5704598/
https://www.ncbi.nlm.nih.gov/pubmed/29209558
http://dx.doi.org/10.1186/s40164-017-0091-4

Ejemplares similares